Print
|
Close
BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Active:
No
Cancer Type:
Hematopoietic Malignancies
NCT ID:
NCT02160041
Trial Phases:
Phase II
Protocol IDs:
CBGJ398XUS04 (primary)
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Novartis Pharmaceuticals Corporation
NCI Full Details:
http://clinicaltrials.gov/show/NCT02160041
Summary
The purpose of this signal seeking study was to determine whether treatment with BGJ398
demonstrates sufficient efficacy in select FGFR pathway-regulated solid tumors and/or
hematologic malignancies to warrant further study.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.